Prothena Corp PLC (PRTA)

Add to Watchlists
Create an Alert
Quickflows
63.46 -1.50  -2.31% NASDAQ Oct 15, 16:00 63.28 -0.18  -0.28% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All PRTA News

News

View All Events

Events

Date Type Description
02/11/2022 08:30 EST Earnings Calls Q4 2021 Earnings Call
11/04/2021 Earnings Results Q3 2021 Earnings Results
08/05/2021 Earnings Results Q2 2021 Earnings Results
05/18/2021 11:00 EST AGM 2020 Annual General Meeting
05/11/2021 Earnings Results Q1 2021 Earnings Results
02/11/2021 Earnings Results Q4 2020 Earnings Results
02/11/2021 08:30 EST Earnings Calls Q4 2020 Earnings Call
11/04/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 60.75M
Total Expenses (TTM) 126.06M
Net Income (TTM) -70.39M

Balance Sheet View Statement

Total Assets (Quarterly) 436.38M
Total Liabilities (Quarterly) 148.17M
Shareholders Equity (Quarterly) 288.21M

Cash Flow Statement View Statement

Cash from Operations (TTM) -35.54M
Cash from Investing (TTM) -0.176M
Cash from Financing (TTM) 101.61M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Prothena Corp PLC is a biotechnology company focuses on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
  • URL: http://www.prothena.com
  • Investor Relations URL: https://ir.prothena.com/
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Nov. 04, 2021
  • Last Earnings Release: Aug. 05, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 63.46
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
PBE Invesco Dynamic Biotech & Genome ETF 2.85%
GQSCX Glenmede Quant US Small Cap Equity 2.49%
SBIO ALPS Medical Breakthroughs ETF 1.69%
AIEQ AI Powered Equity ETF 1.61%
HIL262 Hillsdale US Small Cap Eq Srs F CA$ U$H 1.04%
DWAS Invesco DWA SmallCap Momentum ETF 0.81%
BBC Virtus LifeSci Biotech Clinical Trls ETF 0.79%
IWC iShares Micro-Cap ETF 0.42%

Comparables

Edit
ALKS Alkermes PLC
AMRN Amarin Corp PLC
JAZZ Jazz Pharmaceuticals PLC
NBRV Nabriva Therapeutics PLC
ITRM Iterum Therapeutics PLC

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.